|Awarded On||February 16, 2022|
|Title||The INTERCEPT Trial (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy) for Acute Myeloid Leukemia|
|Award Mechanism||Individual Investigator Research Awards for Clinical Translation|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Courtney DiNardo|
Treatment options for acute myeloid leukemia (AML) have improved rapidly, with nearly a dozen new approvals within 5 years. Yet despite these advances, the majority of AML patients are not cured, and long-term survival remains unacceptably low. Poor long-term outcomes are associated with the presence of residual leukemia, persisting below the limits of standard clinical detection, which expands over time and leads to AML relapse. AML in the relapsed setting has few effective treatment approaches, with an average life expectancy at relapse of < 6 months. With advances in flow cytometric and molecular quantification of measurable residual disease (MRD), we hypothesize that using these techn...